Latest market price
232.94
+3.00+1.30%
RMDQT58ResMed Inc.·NYSE
232.94+1.30%
News
Up 1.3% — ResMed (RMD) Looks Fully Valued After Another Earnings Beat (Yahoo).
Medium confidence
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E21.27EPS (ttm)10.95Insider Own0.99%Shs Outstand140.64MPerf Week-8.00%
Market Cap32.76BForward P/E17.56EPS next Y13.27Insider Trans-2.82%Shs Float139.32MPerf Month6.42%
Enterprise Value32.33BPEG2.54EPS next Q3.03Short Float8.56%Perf Quarter4.39%
Income1.59BP/S5.71EPS this Y8.98%Short Ratio9.24Perf Half Y11.23%
Sales5.73BP/B5.51EPS next Y9.42%ROA19.40%Short Interest11.92MPerf YTD-3.29%
Book/sh42.29P/C32.40EPS next 5Y8.38%ROE25.14%52W High277.67 -16.11%Perf Year-7.66%
Cash/sh7.19P/FCF11.50EPS past 3/5Y19.53% 26.27%ROIC21.24%52W Low180.27 29.22%Perf 3Y67.91%
Dividend Est.2.64 (1.13%)EV/EBITDA14.43Sales past 3/5Y10.21% 12.07%Gross Margin61.18%Volatility3.13% 2.50%Perf 5Y-13.08%
Dividend TTM2.46 (1.06%)EV/Sales5.64EPS Y/Y TTM12.08%Oper. Margin33.13%ATR (14)6.84Perf 10Y265.57%
Dividend Ex-DateNov 12, 2026Quick Ratio1.88Sales Y/Y TTM9.03%Profit Margin27.79%RSI (14)45.08Recom2.74
Dividend Gr. 3/5Y9.53% 7.70%Current Ratio2.65EPS Q/Q14.12%SMA20-2.88%Beta0.75Target Price246.89
Payout38.88%Debt/Eq0.10Sales Q/Q5.91%SMA500.48%Rel Volume1.17Prev Close229.94
Employees11,370LT Debt/Eq0.07EarningsJan 28SMA2003.65%Avg Volume1.35MPrice232.94
IPO DateJun 02, 1995Option/ShortYes / YesEPS/Sales Surpr.8.33% 1.47%Net Debt/EBITDA-0.19Volume1,577,191Change1.30%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-30-26ReiteratedMizuho SecuritiesOutperform$240 → $270
Oct-13-26ReiteratedMizuho SecuritiesOutperform$235 → $240
Sep-15-26UpgradeRBC CapitalSector Perform → Outperform$234 → $262
Aug-31-26ReiteratedKeybancOverweight$255 → $267
Aug-19-26InitiatedRothschild & Co RedburnNeutral$230
Aug-07-26ReiteratedRobert W. Baird$217 → $213
Aug-07-26ReiteratedKeybancOverweight$266 → $255
Jul-21-26ReiteratedUBSBuy$345 → $300
Jul-16-26ReiteratedRBC CapitalOutperform$276 → $234
Jul-15-26ReiteratedMizuhoOutperform$265 → $220
Latest News· Times ET
Oct-30-26
Oct-29-26
Oct-28-26
Oct-26-26
Oct-23-26
Oct-22-26
Company

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2026
6/30/2026
FY 2025
6/30/2025
FY 2024
6/30/2024
FY 2023
6/30/2023
FY 2022
6/30/2022
FY 2021
6/30/2021
FY 2020
6/30/2020
FY 2019
6/30/2019
Total Revenue5,7335,6535,1464,685—————
Cost of Goods Sold Incl. D&A2,2242,2022,0912,030—————
Gross Profit3,5083,4523,0552,655—————
Selling, General and Administrative Excl. Other1,1691,120991917—————
Research and Development394378331308—————
Other Operating Expense464548110—————
Operating Income1,9001,9081,6851,320—————
Interest Expense2501346—————
Unusual Expense
—————————
Non-Operating Income (Expense)138115-9—————
Net Income Before Taxes2,0111,9191,6781,265—————
Income Taxes420396277244—————
Consolidated Net Income1,5931,5231,4011,021—————
Net Income From Continuing Operations1,5931,5231,4011,021—————
Net Income1,5931,5231,4011,021—————
EPS (Recurring)10.9910.449.556.94—————
EPS (Basic, Before Extraordinaries)10.9910.449.556.94—————
EPS (Diluted)10.9510.409.516.92—————
EBITDA2,2402,1531,9131,534—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio21.2718.7427.1327.66—————
Price To Sales Ratio5.815.007.376.01—————
Gross Margin61.1961.0659.3756.67—————
Operating Margin33.1433.7532.7428.18—————
Net Margin27.7926.9427.2321.79—————
Shares Outstanding143145147147—————
Market Capitalization33,31028,25837,92628,139—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$301.25$267.78$234.31$200.84$167.37● Close Price0.00M0.97M1.95M2.92M3.89MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Rider Michael JGlobal General CounselOct 23 '26Sale255.00400102,00012,318Oct 26
Farrell Michael J.Chairman and CEOOct 07 '26Sale226.334,9911,129,637479,803Oct 08
Farrell Michael J.Chairman and CEOOct 07 '26Option Exercise146.344,991730,383484,794Oct 08
Farrell Michael J.Chairman and CEOSep 08 '26Option Exercise146.344,991730,383471,247Sep 10
Farrell Michael J.Chairman and CEOSep 08 '26Sale222.444,9911,110,191466,256Sep 10
FARRELL PETER CDirectorSep 02 '26Sale234.73970227,68851,803Sep 04
Farrell Michael J.Chairman and CEOAug 07 '26Sale205.694,9911,026,596466,256Aug 11
Farrell Michael J.Chairman and CEOAug 07 '26Option Exercise146.344,991730,383471,247Aug 11
FARRELL PETER CDirectorAug 05 '26Sale225.008,0001,800,00052,773Aug 06
Farrell Michael J.Chairman and CEOJul 07 '26Option Exercise146.344,991730,383471,214Jul 09
Farrell Michael J.Chairman and CEOJul 07 '26Sale218.554,9911,090,771466,223Jul 09
Farrell Michael J.Chairman and CEOJun 08 '26Option Exercise146.344,991730,383471,214Jun 09
Farrell Michael J.Chairman and CEOJun 08 '26Sale193.964,991968,064466,256Jun 09
Farrell Michael J.Chairman and CEOMay 07 '26Option Exercise146.344,991730,383471,214May 11
Farrell Michael J.Chairman and CEOMay 07 '26Sale207.824,9911,037,233466,223May 11
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.